The core protein of a recently described small proteoglycan, proteoglycan-100, was localized in fetal human tissues by indirect immunocytochemistry and compared with the localization of known members of the small proteoglycan family. Co-localization of decorin and proteoglycan-100 was seen in bone tissue but decorin and proteoglycan-100 exhibited a substantially divergent distribution in fetal skin, cartilage and in the mineralization zone of the growth plate. Proteoglycan-100 was also found in striated muscle, nerve fibers, and synovial tissue. Immunostaining of a chondro- Forschungsgcmeinschaft (SFB. Project B2) blastic osteosarcoma demonstrated chondroid cells selectively expressing either proteoglycan-100 or decorin. CO-expression of both small proteoglycans was observed in sections from a chordoma. In fetal bone and in the two tumors, colocalization of proteoglycan-100 and of biglycan was also found. These results provide evidence of the wide and characteristic distribution of proteoglycan-100. ( J Hhtocbem   Cytochem 41:13-19, 1993) 
Introduction
Human mesenchymal tissues are known to contain two different small chondroitinldermatan sulfate proteoglycans, biglycan and decorin (5, 6, 11, 13, 16, 19) . The secreted form of human biglycan (proteoglycan I) consists of a protein of M, 37,983, which is usually substituted with two glycosaminoglycan chains and two asparaginebound oligosaccharides (6, 16) . The secreted form of human decorin (proteoglycan 11) is characterized by a core protein of Mr 36,319, a single glycosaminoglycan chain, and either two or three N-linked oligosaccharides (8.13). The core proteins of both proteoglycans show extensive homologies, especially in their central portions which consist of leucine-rich repeats. Within a given tissue the polysaccharide composition of both proteoglycans is similar. However, they show tissue-related heterogeneity, i.e., being of chondroitin sulfate type in bone and of dermatan sulfate type in cartilage (3, 5, 14) . Recently a further member of the small proteoglycan family has been described which is a major product of human osteosarcoma cells but is also synthesized by cultured skin fibroblasts (21) . Its 78 KD core protein is substituted with Nand 0-glycosidically linked oligosaccharides and with a single chondroitin-6-sulfate chain. On enzymatic removal of the glycosaminoglycan chain, the mature core protein behaves like a protein with an apparent molecular mass of about 100 KD, and the proteoglycan has therefore tentatively been named proteoglycan-100 (PG-100).
From the tissue distribution of decorin (1, 17, 18, 26) and from in vitro studies of Type I and Type I1 collagen with this proteoglycan (22) (23) (24) . it was proposed that decorin is involved in the regulation of collagen fibrillogenesis. It also inhibits the adhesion of fibroblasts to fibronectin (15, 27) . Both biglycan and decorin may form inactive complexes with transforming growth factor-p and could therefore participate in several aspects of cell regulation (20). However, until now no specific function has been ascribed to biglycan. Under the usual assay conditions it did not interact with collagen fibrils (10,21) and did not decorate collagen fibrils in human skin (7) . Since in human tissues the expression and localization of decorin and biglycan were substantially divergent and sometimes mutually exclusive, it has been assumed that the latter proteoglycan is most likely involved in functions other than matrix production and assembly (1). Likewise, a biological role of PG-100 has not yet been established. The proteoglycan from human osteosarcoma cells does not bind to Type I collagen fibrils (21), whereas such an association was observed in the case of a chondroitiddermatan sulfate proteoglycan with a core protein of 101 KD which was synthesized by cultured rat hepatic lipocytes (28).
The objective of the present study was to compare the localization of PG-100 and decorin in human skin and human skeletal tissues and tumors and in several other connective tissues for better 14 BOSSE, SCHWARZ, VOLLMER, KRESSE addressing the question of what the ultimate function of PG-100 may be. A chordoma was also included in this study because of its high glycosaminoglycan content (12).
Materials and Methods
Immunochemical Reagents. Rabbit antibodies against PG-100 were those used previously (21). They were raised against the PG-100 core protein which was purified from the secretions of the human osteosarcoma cell line MG-63 by chromatography on DEAE-Trisacryl, equilibrium density centrifugation, and preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), the latter procedure being performed after digestion with chondroitin ABC lyase. As predicted, the antiserum contained antibodies against unsaturated uronosyl residues of the remaining oligosaccharide stubs in addition to those against determinants on the core protein. Chondroitin ABC lyase treatment of tissue sections was therefore avoided throughout this study. The antiserum did not crossreact with biglycan. which is abundant in the secretions of osteosarcoma cells (21), but showed crossreactivity with decorin when it was present in excess, as in the secretions of skin fibroblasts (8) . Therefore, 100 pI of the PG-100 antiserum were incubated for 2 days at 4°C with about 7 pg of PG-100 core protein, purified from the media of osteosarcoma cells, under standard immunoprecipitation conditions. After centrifugation, soluble antibodies reacted neither with [ 35S]methionine-labeled decorin nor with [3sS]-methionine-labeled . When this pre-absorbed antiserum was used for immunohistochemistry it failed to give a positive immune reaction (see below). A 0.5-ml portion of the antiserum was also purified on a O.S-ml column of an affinity matrix prepared by the reaction of 2 mg of decorin from fibroblast secretions with 0.5 ml of CNBr-activated Sepharose 4B (Pharmacia; Uppsala, Sweden) according to the instructions of the manufacturer. Non-adsorbed antibodies failed to react with decorin after SDS-PAGE and Western blotting under conditions in which a strong reaction with the decorin antiserum was obtained (9).
An antiserum against a synthetic peptide corresponding to residues 11-24 of the secreted form of biglycan (6) was raised in a rabbit after conjugating the peptide (kindly provided by Dr. B. Schmidt, Dept. Biochemistry 11, University of Gottingen) with bovine serum albumin under analogous conditions as described (21). Briefly, 3.5 mg of the peptide were dissolved in 1 ml of water and allowed to react with 0.6 ml of l-ethyl-3-(3-dimethyI-aminopropy1)-carbodiimide (Sigma; St Louis, MO) for 5 min. the pH being maintained between 4.5 and 5.1. Bovine serum albumin ( 5 mg in 0.4 ml of water) was then added and the reaction continued for 16 hr at am-bient temperature. After dialysis against 10 mM sodium phosphate, pH 7.4, containing 0.15 M NaCl (PBS), the conjugate was divided into three portions for the immunization of a rabbit. Intracutaneous injections wete given on Days 0, 20, and 30. For the first injection the antigen was mixed with complete, for booster injections with incomplete Freund's adjuvant. Sera were collected 7 and 10 days after the last injection. This antiserum reacted neither with decorin nor with PG-IO0 (9).
For raising a rabbit antiserum against decorin core protein, the antigen 7~a s purified from the secretions of cultured skin fibroblasts (8) and deglycosylated as follows. Lyophilized decorin (0.4.5 pmol of hexuronic acid) was incubated on ice and under nitrogen with a mixture of 80 pl of trifluoromethansulfonic acid and 40 pl of anisole. After 5 hr the sample was extracted with 660 pl of pyridi1ie:water:diethyl ether (1:1:3 by vol), the ether phase was removed and the remaining solution dialyzed against PBS. The immunization protocol was as described above. Protein A-Sepharosebound antibodies from the antiserum reacted neither with [35S]-methionine-labeled biglycan nor with labeled PG-100 from the secretions of MG-63 osteosarcoma cells and of fibroblasts.
Immunostaining of Proteoglycans. Standard tissue preparations embedded in paraffin were obtained from a 17-week-old fetus, a chordoma, and an osteoblastic osteosarcoma with a chondroblastic component. Sections 3 pm thick were placed on lysine-coated slides and dried overnight at 37'C. The sections were deparaffinized with xylol. Tissue sections were first treated for 20 min with 20 mM Tris-HCI, pH 7.4. containing 0.15 M NaCl (Buffer A) and 1% bovine serum albumin. They were then incubated for 45 min with antisera against PG-100, decorin, and biglycan dilured ~1 0 , 1:100, and 1:20 respectively, with Buffer A. Excess antibody was removed by washing five times with Buffer A. For the visualization of PG-100 the immunochemical detection system was adapted from Cordell et al. (4) . The sections were incubated for 30 min with mouse anti-rabbit IgG (Dako; Santa Barbara, CA), diluted 1:125 with Buffer A, then with rabbit anti-mouse IgG (Dako) diluted 1:30, and finally for 60 min with a 1:lOO dilution of a complex of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP; Dianova, Hamburg, Germany). Naphthol AS-BI phosphate with an admixture of neofuchsin scrved as substrate; endogenous alkaline phosphatase was suppressed bylevamisole as described (4), and post-staining was with hematoxylin. For the immunolocalization of either decorin or biglycan an indirect peroxidase method was used. Endogenous peroxidase was suppressed by treatment with 10 mM sodium azide and 29 mM HzOz for 10 min at room temperature. Then, peroxidase-labeled goat anti-rabbit IgGlIgM antibodies (Dianova) diluted 1:150 with Buffer A were added, and color was developed by incubation with 2.8 mM 3,Y-diaminobenzidine H 2 0 2 (25) . The staining procedure was also performed in an opposite manner, i.e., decorin was visualized by the APAAP technique and PG-100 by the indirect peroxidase method. In double labeling, indirect peroxidase staining for the visualization of either decorin or biglycan was performed first, followed by the APAAP procedure for the visualization of PG-100.
Pre-immune sera from the animals in which primary antibodies were raised and the pre-absorbed PG-100 antiserum served as negative controls. In double labeling either one or the other of the two primary antisera was omitted for control purposes. It was ascertained that after indirect peroxidase staining with one antiserum a negative result was obtained when the APAAP procedure was employed in the absence of the other of the primary antisera. No interference was obtained in single labeling experiments when the substrates of both enzymes, i.e., of peroxidase and of alkaline phosphatase, were applied or when either one or the other of the substrates was omitted.
Results

Immunolocdization of PG-100 and Decorin
Bone and Cartilage. Since PG-100 had first been demonstrated in the secretions of cultured human osteosarcoma cells, we first investigated the localization of PG-100 in human bone. With the most sensitive APAAP technique and a monospecific antiserum without crossreactivity towards decorin, there was strong immunoreactivity for PG-100 in osteoblasts (Figures la and Ib) and occasionally in osteoclasts ( Figure IC) in the epiphyseal plate of a fetal finger. Analogous staining of similar sections from the same block for decorin demonstrated the presence of this proteoglycan in osteoblasts and osteoclasts. However, in contrast to PG-100, decorin was also detectable extracellularly in the mineralization zone, showing a rim-like pattem (Figure 2) . A similar distribution of reactive epitopes of both proteoglycans was obtained when the indirect peroxidase method was used in place of the APAAP staining protocol (not shown). This indicated that both methods were equally well suited for immunolocalization of the two proteoglycans in this tissue. Additional sections ofthe growth plate revealed positive staining for PG-100 in individual chondrocytes of the epiphyseal cartilage (Figure 3a) , whereas an absence of immunoreactive material in cartilage and an extracellular localization in the mineralization zone was observed when the decorin-specific antiserum was em-ployed ( Figure 3b ). As expected, double staining for PG-100 and decorin resulted in a mixed color in the osseous tissue, indicating co-localization of PG-100 and decorin (Figure 3c ). In periosteal regions too, co-expression of PG-100 and decorin was indicated by the occurrence of a mixed color (Figure 4a ). Again, underlying cartilaginous tissue showed immunostaining for PG-100 exclusively in some scattered chondrocytes (Figure 4b ) and in circumscribed perichondrial areas (Figure 4c ).
Similar differences in the expression patterns of the two small proteoglycans in cartilage were also observed in a capillary bud within the chondral structures of a finger. With the APAAP technique, PG-100 could be demonstrated in the vascular endothelium, being diffusely distributed in the cytoplasm. Positively stained chondrocytes with a very faint immune reaction were only sporadically found in the vicinity of the vascular endothelium ( Figure Sa) . Decorin, on the contrary, was not detected when analyzed by the indirect peroxidase method (Figure 5b ). In the double staining procedure only the red color of the PG-100 stain could be seen (Figure 5c ).
Fetal Skin. Fetal skin showed strong immunoreactivity with the PG-100 antiserum in the immature squamous epithelium, which still displayed the initial vesicular arrangement. The underlying corium stained very weakly for PG-100 ( Figure 6a ). This layer, however, presented a positive reactivity with decorin-specific antibodies (Fig. 6b) . Double labeling supported the conclusion of a divergent localization of PG-100 and decorin in human fetal skin by a red-colored epidermis and a brown color of the corium (Figure 6c ). Striated Musde. PG-100 reactivity was detected in striated muscle. The immune reaction showed a regionally different pattern, with areas of faint and areas of intense staining within the muscle cells (Figure 7a ). Nerve Fibers. PG-100 was demonstrated in nerve fibers by a faint immune reaction. The surrounding mesenchymal tissue remained unstained (Figure 7b ). Synovial Tissue. In the synovial tissue from a finger joint, PG-100 was demonstrated by a faint immune reaction in the synovial cells (Figure 7c ).
Osteosarcoma. The area shown in Figure 8a demonstrates the presence of both PG-100 and decorin. PG-100 could be found in I chondroblastic tumor cells, some of which co-expressed decorin whereas others did not (Figures 8b and 8c) . Still other tumor cells, however, demonstrated neither PG-100 nor decorin immune reactivity. Decorin was additionally found in the stroma, especially in the vicinity of the tumor osteoid ( Figure 8a) .
Chordoma.
A rather intense staining reaction for PG-100 was detected in a chordoma. PG-100 was evenly distributed in tumor cells of the stellate as well as of the physaliforous type (Figure 9a) . A differentiated immune expression could not be demonstrated. Double labeling for PG-100 and decorin resulted in the formation of a mixed red and brown color in most cells, indicating the coexpression of both proteoglycans (Figure 9b ). This positive reddishbrown immune reaction contrasted with the control staining in which only decorin antibodies were employed and the anti-PG-100 serum was omitted; here we obtained a brown color exclusively after immunostaining (not shown). In addition, after omitting both of the primary antibodies (it., anti PG-100 and anti-decorin) the procedure for both detection systems (i.e., peroxidase and APAAP) was performed and completely negative staining resulted ( Figure  9c ). It should be noted that analogous controls were performed for all tissues investigated, and in all cases no indication for unspecific staining was obtained.
Immunolocalization of PG-100 and Biglycan
The availability of a biglycan-specific antiserum made it possible to compare the localization of the latter proteoglycan with that of PG-100 in selected tissues. It could be shown that in fetal bone and also in the chondroblastic osteosarcoma and the chordoma biglycan co-distributes with PG-100 (Figures 10a-10c ).
Discussion
This report provides the first description of the presence in tissues of a newly discovered proteoglycan, tentatively designated PG-100. This proteoglycan had been detected thus far only in cultured human osteosarcoma cells and skin fibroblasts. Together with biglycan it represented the major polyanionic secretory product of osteosarcoma cells, whereas it was a minor component in the secretions of skin fibroblasts (21). The latter cells are characterized by the predominant production of decorin (8). These results from in vitro studies are mirrored in the present investigation. A strongly positive immune reaction for PG-100 was found in bone tissue, whereas the dermis was stained only weakly. In addition, keratinocytes and individual chondrocytes gave a positive immune reaction. The latter observations is in accordance with the fact that only small amounts of PG-100 could be isolated from bovine articular cartilage (K. Schwarz, B. Ober, and H. Kresse, unpublished result).
PG-100 was localized by immunostaining preferentially within the cells and not preferentially as a component of the extracellular matrix. This is surprising because in cultured cells PG-100 became secreted after biosynthesis with a half-life of about 50 min (21). However, the epitopes recognized by the antibodies are not known, and it seems possible that in tissue sections the antigenic determinants are masked by the polyanionic glycosaminoglycan chains. Enzymatic removal of the polysaccharide chains was avoided because of the presence of antibodies against the unsaturated oligosac-charides being created by the respective enzymes. Unfortunately, the available amounts of PG-100 were not large enough to make possible the removal of these antibodies by affinity chromatography.
The most remarkable finding of this study was the substantially divergent distribution of PG-100 and decorin in some tissues and a co-distribution in others. Decorin could not be stained in cartilage, but it had previously been shown that enzymatic removal of glycosaminoglycans was required for a visualization of decorin core protein (26). With this methodological restriction, decorin was positively immunolocalized in all connective tissue matrices investigated. On the contrary, PG-100 was visualized in keratinocytes and in certain areas of cartilage. However, both proteoglycans were detected in bone, PG-100 being found preferentially in osteoblasts and decorin in the mineralization zone. Osteoclasts could express both proteoglycan species. From these results it can be deduced that the biosynthesis of both proteoglycans is ddferentially regulated. A similar conclusion had been drawn from the different effects of TGFP on the biosynthesis of the small proteoglycans in osteosarcoma cells (2).
Although it is obvious that the presence of PG-100 is not restricted to bone, it is nevertheless predominantly expressed in this tissue. A chondroblastic osteosarcoma also showed a strongly positive immune reaction. In connection with the predominant expression of PG-100 by cultured osteosarcoma cells, it can be suggested that PG-100 is a potential marker of bone-derived tumors. However, much larger numbers of tumors must be analyzed before a diagnostic benefit of PG-100 determinations can be evaluated.
